Maravai LifeSciences Holdings, Inc.
MRVINASDAQHealthcare● Active
$5.13
+$0.11(+2.09%)
Market Cap$1.4B
P/E Ratio—
52W High$5.19
52W Low$1.99
Maravai LifeSciences Holdings, Inc. (MRVI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MRVI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.01
Est. -$0.05 · +120.0%
Revenue
$0.07B
Est. $0.05B · +24.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
MRVI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.05 | — | — | — | $0.05B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.05 | $0.01 | +120.0% | $0.07B | $0.05B | +24.2% |
| ▲ Q1 FY2026 | Feb 25, 2026 | -$0.07 | -$0.04 | +42.9% | $0.05B | $0.05B | +1.7% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.06 | -$0.08 | -33.3% | $0.04B | $0.05B | -15.2% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.06 | -$0.08 | -33.3% | $0.05B | $0.05B | -5.4% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.07 | -$0.08 | -14.3% | $0.05B | $0.04B | +6.5% |
| ▼ Q1 FY2025 | Mar 18, 2025 | -$0.03 | -$0.06 | -100.0% | $0.06B | $0.06B | -2.4% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.01 | -$0.02 | -150.0% | $0.07B | $0.06B | +15.1% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.01
EPS Est.
-$0.05
EPS Surpr.
+120.0%
Revenue
$0.07B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.07
EPS Surpr.
+42.9%
Revenue
$0.05B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
$0.04B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
$0.05B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-14.3%
Revenue
$0.05B
Q1 FY2025
Mar 18, 2025Miss
EPS Actual
-$0.06
EPS Est.
-$0.03
EPS Surpr.
-100.0%
Revenue
$0.06B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-150.0%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.03 | $-0.03 | $-0.03 | 2 |
| Q3 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q1 FY2027 | $-0.01 | $-0.01 | $-0.01 | 2 |
| Q4 FY2026 | $-0.04 | $-0.03 | $-0.03 | 2 |
| Q3 FY2026 | $-0.05 | $-0.05 | $-0.05 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +120.0% | $3.94 | $3.94 | +0.00% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +42.9% | $3.12 | $3.26 | +4.49% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -33.3% | $2.87 | $2.89 | +0.70% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -33.3% | $2.20 | $2.06 | -6.36% |
| ▼ Q2 FY2025 | May 12, 2025 | -14.3% | $1.98 | $2.12 | +7.07% |
| ▼ Q1 FY2025 | Mar 18, 2025 | -100.0% | $2.64 | $2.58 | -2.27% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -150.0% | $8.03 | $7.84 | -2.37% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -100.0% | $9.09 | $9.10 | +0.11% |
Q2 FY2026+0.00%
Report Date
May 7, 2026
EPS Beat/Miss
+120.0%
Price Before
$3.94
Price After
$3.94
Q1 FY2026+4.49%
Report Date
Feb 25, 2026
EPS Beat/Miss
+42.9%
Price Before
$3.12
Price After
$3.26
Q4 FY2025+0.70%
Report Date
Nov 6, 2025
EPS Beat/Miss
-33.3%
Price Before
$2.87
Price After
$2.89
Q3 FY2025-6.36%
Report Date
Aug 11, 2025
EPS Beat/Miss
-33.3%
Price Before
$2.20
Price After
$2.06
Q2 FY2025+7.07%
Report Date
May 12, 2025
EPS Beat/Miss
-14.3%
Price Before
$1.98
Price After
$2.12
Q1 FY2025-2.27%
Report Date
Mar 18, 2025
EPS Beat/Miss
-100.0%
Price Before
$2.64
Price After
$2.58
Q4 FY2024-2.37%
Report Date
Nov 7, 2024
EPS Beat/Miss
-150.0%
Price Before
$8.03
Price After
$7.84
Q3 FY2024+0.11%
Report Date
Aug 7, 2024
EPS Beat/Miss
-100.0%
Price Before
$9.09
Price After
$9.10
Avg Beat Reaction+2.25%
Avg Miss Reaction-0.52%
Beat Rate2 / 8 quarters
Largest Move+7.07% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MRVI ends December
Maravai LifeSciences Holdings, Inc. (MRVI) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.01 — beating the analyst consensus of $-0.05 by +120.0%. MRVI has beaten EPS estimates for 2 consecutive quarters. The next MRVI earnings date is expected around September 1, 2026.
Each quarter, investors track MRVI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MRVI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MRVI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MRVI earnings · 5 questionsMaravai LifeSciences Holdings, Inc.'s next earnings report is expected around September 1, 2026. MRVI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MRVI historically reports after market close (AMC).
MRVI earnings datewhen is MRVI earningsMRVI next earnings datewhen does MRVI report earningsMRVI earnings calendar
▸ Source: FMP · Maravai LifeSciences Holdings, Inc. SEC filings · US GAAP · Maravai LifeSciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026